Board of Directors of Neurimmune Subone AG

Roger M Nitsch serves as CEO of the Neurimmune Group and President and Member of the Board of Neurimmune Subone AG. A neuroscientist with a background in medicine, Roger is recognized as an opinion leader in neurodegenerative diseases with over 30 years of experience in Alzheimer’s disease research, and as a pioneer in the development of therapeutic approaches for neurodegenerative diseases. A Potamkin Prize winner, Member of the German Academy of Sciences and Professor emeritus at the University of Zurich, Roger served as a founding director of the Institute for Regenerative Medicine (IREM), University of Zurich.

Jan Grimm is a neuroscientist with 20 years of experience in drug discovery and development in US and European biotech. Jan co-founded Neurimmune in 2006, and served as the company's founding CEO. Before joining Neurimmune he led the Alzheimer’s disease research efforts at Rinat Neuroscience Corp. in San Francisco that was acquired by Pfizer in 2006. He received a PhD degree from Max Delbrück Center for Molecular Medicine and Humboldt University Berlin.

Christoph Hock is a board-certified psychiatrist and an internationally recognized expert on Alzheimer's disease and related disorders. He co-founded Neurimmune in 2006 and acts as Chief Medical Officer (CMO). Previously, Christoph served as Vice-President Medicine and Science on the executive board of the University of Zurich, and as member of the Swiss National Science Foundation's Research Council. He currently holds a part-time professorship on Biological Psychiatry at the Institute for Regenerative Medicine (IREM), University of Zurich.